KR100832404B1 - Extract of Cuscutae Semen for preventing production of hair loss causative agent and its composition - Google Patents
Extract of Cuscutae Semen for preventing production of hair loss causative agent and its composition Download PDFInfo
- Publication number
- KR100832404B1 KR100832404B1 KR1020060053227A KR20060053227A KR100832404B1 KR 100832404 B1 KR100832404 B1 KR 100832404B1 KR 1020060053227 A KR1020060053227 A KR 1020060053227A KR 20060053227 A KR20060053227 A KR 20060053227A KR 100832404 B1 KR100832404 B1 KR 100832404B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- alpha
- reductase
- hair loss
- testosterone
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 약용식물로부터 얻은 테스토스테론 5알파-리덕타아제 저해용 활성 추출물에 관한 것으로, 더욱 상세하게는 전통적으로 동양에서 사용해온 약용식물인 토사자 (兎絲子), 맥문동(麥門冬), 괴화(槐花)로부터 테스토스테론 5알파-리덕타아제의 작용을 저해하여 탈모의 원인이 되는 디하이드로테스토스테론 생성을 억제할 수 있는 활성 추출물과 이를 효율적으로 추출하는 방법, 그리고 그 추출물들을 유효성분으로 함유하는 탈모 예방 및 치료의 원료, 건강식품, 화장품, 생약제에 관한 것이다.The present invention relates to an active extract for inhibiting testosterone 5 alpha-reductase obtained from a medicinal plant, and more particularly, tosa, pulmonosa, and lump of medicinal plants traditionally used in the Orient. An active extract capable of inhibiting the action of testosterone 5 alpha-reductase from saturation and inhibiting the production of dihydrotestosterone, which causes hair loss, a method of extracting it efficiently, and containing the extract as an active ingredient It relates to raw materials, health foods, cosmetics and herbal medicines for the prevention and treatment of hair loss.
토사자 (兎絲子), 맥문동(麥門冬), 괴화(槐花), 테스토스테론 5알파-리덕타아제, 디하이드로테스토스테론, 전립선 비대증, 여드름, 탈모 예방 및 치료 Earth and sand, Macmundong, lump flower, Testosterone 5 alpha-reductase, Dihydrotestosterone, Prostatic hypertrophy, Acne, Hair loss prevention and treatment
Description
도 1은 방사선 표지된 테스토스테론과 DHT의 박층 크로마토그래피 이미지이다.1 is a thin layer chromatography image of radiolabeled testosterone and DHT.
도 2는 토사자 (兎絲子, Cuscutae Semen)추출물의 농도별 테스토스테론 5알파-리덕타아제 저해 정도를 나타낸 그래프이다.2 is the earth and sand (兎絲子, Cuscutae) Semen ) is a graph showing the
도 3은 괴화(槐花, Sophorae Flos) 추출물의 농도별 테스토스테론 5알파-리덕타아제 저해 정도를 나타낸 그래프이다.3 is a graph showing the degree of inhibition of
도 4는 맥문동(麥門冬, Liriopis Tuber) 추출물의 농도별 테스토스테론 5알파-리덕타아제 저해 정도를 나타낸 그래프이다.Figure 4 is a graph showing the
도 5는 C57BL/6 마우스를 제모 부위에 토사자 (兎絲子), 맥문동(麥門冬), 괴화(槐花) 추출물을 20일간 경피 도포하여 모발이 성장한 형태를 보여주는 이미지이다.FIG. 5 is an image showing the growth of hair by transdermal coating of Tosa, Macmun-dong, and lump flower for 20 days on the hair removal site of C57BL / 6 mice. FIG.
도 6은 C57BL/6 마우스의 제모 부위에 토사자 (兎絲子), 맥문동(麥門冬), 괴화(槐花) 추출물을 20일간 경피 도포하여 모발이 성장한 면적을 나타낸 그래프이다.FIG. 6 is a graph showing the area in which hairs were grown by transdermal coating of earth and sand, macmundong, and lump flower extracts on the hair removal site of C57BL / 6 mice for 20 days.
도 7은 C57BL/6 마우스의 제모 부위에 토사자 (兎絲子), 맥문동(麥門冬), 괴화(槐花) 추출물을 20일간 경피 도포하여 성장한 모발의 무게를 나타낸 그래프이다.FIG. 7 is a graph showing the weight of hair grown by transdermal coating of earth and sand, macmundong, and lump flower extracts on the hair removal site of C57BL / 6 mice for 20 days.
본 발명은 전립선 비대증, 여드름, 남성형 탈모증의 치료에 사용될 수 있는 새로운 5알파-리덕타아제 저해제에 관한 것으로 더욱 상세하게는 활성성분으로 괴화, 토사자, 맥문동의 추출물을 함유하는 5알파-리덕타아제 저해제에 관한 것이다.The present invention relates to a novel 5-alpha-reductase inhibitor which can be used for the treatment of enlarged prostate, acne and androgenetic alopecia, and more particularly, 5-alpha-reductase containing extracts of lumps, tosa and pulmonary dong as active ingredients. It relates to an inhibitor.
5알파-리덕타아제는 전립선, 진피층, 피지선, 모낭 등에서 발견되는 효소로서 남성호르몬인 테스토스테론을 디하이드로테스토스테론 (dihydrotestosterone, DHT)으로 전환시키는 역할을 한다. DHT는 안드로겐 수용체와 결합하여, 핵 안으로 들어가 전사 인자(transcription factor)로 작용하여, 전립선의 성장 및 분화를 촉진하고 항상성과 기능을 유지하는데 테스토스테론보다 더 큰 역할을 한다. 나이가 들면 남성호르몬 테스토스테론이 5-α 리덕타제에 의해 DHT으로 바뀌는 양이 많아지고 이 DHT는 전립선의 성장 및 분화를 촉진하게 돼 결국 전립선 암, 전립선 비대증에 걸려 배뇨곤란, 약뇨, 빈뇨, 야간빈뇨 등 여러 가지 증상을 유발하게 된다. 두피에서는 DHT의 증가에 따라 앞이마와 정수리에 분포하는 hair follicle 이 점진 적으로 작아지게 되면, 이들 세포로부터 생성되는 머리카락은 정상상태보다 더 짧아지고 가늘어지며 옅은 색을 띠게 된다. 이들 세포에서는 anagen phase가 이전보다 단축되거나 anagen phase로의 진입이 지연되어, 결과적으로 anagen/telogen 비율이 감소하거나 새로운 anagen hair가 생성되기 전에 telogen hair가 이탈된다. 대표적인 5알파-리덕타아제 저해제인 Finasteride (MSD ltd.)는 4-azasteroid 합성 유도체로서 미국 FDA 인증을 거쳐 실제로 전립선 비대증 치료제 및 남성형 탈모치료제로 이용되고 있다.5-alpha-reductase is an enzyme found in the prostate, the dermis, sebaceous glands, and hair follicles, and converts testosterone, a male hormone, to dihydrotestosterone (DHT). DHT binds to androgen receptors, enters the nucleus and acts as a transcription factor, which plays a larger role than testosterone in promoting growth and differentiation of the prostate and maintaining homeostasis and function. As we age, male hormone testosterone increases to 5-HT reductase to DHT, which promotes the growth and differentiation of prostate gland, resulting in prostate cancer, prostatic hypertrophy, difficulty urinating, weakness, frequent urination, and nocturia. This can cause a variety of symptoms. In the scalp, as the hair follicles in the forehead and the crown gradually decrease as the DHT increases, the hairs produced from these cells become shorter, thinner and lighter than normal. In these cells, the anagen phase is shorter than before or delayed entry into the anagen phase, resulting in a decrease in the anagen / telogen ratio or the release of telogen hair before new anagen hair is produced. Finasteride (MSD ltd.), A representative 5-alpha-reductase inhibitor, is a 4-azasteroid synthetic derivative that has been approved by the US FDA and is actually used as a treatment for prostatic hyperplasia and male hair loss.
그러나, Finasteride는 성욕감퇴, 발기부전 등의 부작용을 나타내는 등 사용대상과 용법에 있어서 많은 제한을 받고 있어 실용성이 적고 상당한 주의가 필요한 실정이다.However, Finasteride is limited in terms of its use and usage, such as side effects such as decreased libido and erectile dysfunction, and thus requires little attention and practicality.
본 발명에서는 5알파-리덕타아제를 효과적으로 저해하면서도 Finasteride와 같은 부작용을 최소화한 저해제를 찾기 위해 한방에서 사용되어져 온 모든 약용식물을 포함한 자생식물 수천종의 추출물을 대상으로 집중적인 탐색을 수행한 결과 토사자, 괴화, 맥문동 각각의 추출물이 5알파-리덕타아제 활성을 저해하는 것을 확인하고 본 발명을 완성하였다.In the present invention, the results of intensive search on thousands of extracts of native plants, including all medicinal plants that have been used in herbal medicine to effectively inhibit 5 alpha-reductase and minimize side effects such as Finasteride It was confirmed that the extracts of the earth and sand, lumps, and pulses each inhibit 5 alpha-reductase activity and completed the present invention.
본 발명은 토사자, 괴화, 맥문동에서 분리한 추출물의 테스토스테론 5알파-리덕타아제 저해활성을 그 특징으로 한다.The present invention is characterized in that the
본 발명에서 토사자, 괴화, 맥문동의 추출물을 제조함에 있어서,In the present invention to prepare an extract of earth and sand, lumps, pulses,
(1) 토사자, 괴화, 맥문동을 건조하여 분쇄하는 단계;(1) drying and pulverizing the earth and sand, lump, pulmonary dong;
(2) 정제수를 생약제 함량대비 5-10 배량을 넣어 열탕 추출하는 단계;(2) extracting hot water by adding 5-10 times the amount of purified water to the herbal medicine content;
(3) 정제수 추출용액을 여과지를 사용하여 여과한 뒤 동결건조하는 단계를 포함하는 토사자, 괴화, 맥문동으로부터 테스토스테론 5알파-리덕타아제 저해활성을 지닌 추출물을 분리하는 방법을 또 다른 특징으로 한다.(3) Another method is to separate the
본 발명은 상기 추출 방법에 따라 분리된 토사자, 맥문동, 괴화 추출물들을 유효성분으로 하는 테스토스테론 5알파-리덕타아제의 활성을 저해하는 우수한 효과가 있으므로 전립선 비대증, 여드름, 탈모의 예방과 치료의 원료, 건강식품, 화장품, 생약제 등으로 사용하는 것을 포함한다.The present invention has an excellent effect of inhibiting the activity of
이와 같이 본 발명을 더욱 상세히 설명하면 다음과 같다.
본 발명은 5알파-리덕타아제 활성 저해효과의 측정방법으로서 LNCaP 세포주, DU-145 세포주에 이 효소의 기질인 테스토스테론과 함께 약용식물 추출물들을 처리하여 효소 활성을 우수하게 저해하는 효과를 보이는 토사자, 맥문동, 괴화 추출물에 관한 것이다.As described above in more detail the present invention.
The present invention is a method for measuring the inhibitory effect of the 5 alpha-reductase activity, the earth and sand, which shows the effect of inhibiting the enzyme activity by treating medicinal plant extracts with testosterone which is the substrate of this enzyme in LNCaP cell line, DU-145 cell line, It relates to the pulsed dong, lump extract.
삭제delete
즉, 토사자 (兎絲子), 맥문동(麥門冬), 괴화(槐花)로부터 얻은 추출물이 5알파-리덕타아제의 활성을 저해하는 효과를 갖고있는 것을 처음으로 관찰하여 상기조성물을 유효성분으로 함유하는 5알파-리덕타아제 저해효과를 지닌 활성조성물을 개발하였다.In other words, the extract obtained from earth and sand, Macmun-dong, and lump flower had the effect of inhibiting the activity of 5-alpha-reductase for the first time. An active composition with 5 alpha-reductase inhibitory effect was developed.
본 발명에 따른 활성조성물 이외에도 약학적으로 허용가능한 담체 또는 부형제를 사용하여 정제, 산제, 과립, 캅셀제, 연고제, 현탁액, 유화액 또는 비경구 투여용의 단위 투여형 또는 수회 투여형 제제로 제형화하여 사용할 수 있다.In addition to the active compositions according to the invention, pharmaceutically acceptable carriers or excipients may be used in the form of unit or multiple dosage forms for tablets, powders, granules, capsules, ointments, suspensions, emulsions or parenteral administration. Can be.
이하 본 발명을 실시예에 의거하여 더욱 상세히 설명하겠는 바, 본 발명이 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to Examples.
실시예Example 1: 토사자 ( 1: earthenware ( 兎絲子兎 絲 子 ), 맥문동(), Macmundong ( 麥門冬麥 門冬 ), ), 괴화(槐花)의Lump of flowers 추출물 분리 Extract separation
건조된 토사자, 맥문동, 괴화를 분쇄하여 시료양 대비 5-10배량의 정제수를 넣어 활성물질이 용출할 수 있도록 70도 이상에서 2시간씩 열탕 추출하였다. 이후, 정제수 추출용액을 여과지를 사용하여 여과한 뒤 동결건조하여 사용하였다.The dried earthenware, pulmundong, and lumps were pulverized, and 5-10 times the amount of purified water was added to the sample to extract the hot water at 70 degrees or more for 2 hours to elute the active substance. Thereafter, the purified water extract solution was filtered using a filter paper and then used by lyophilization.
실시예Example
2: 테스토스테론 2:
5알파-리덕타아제는 테스토스테론을 디하이드로테스토스테론으론 전환시키는 역할을 한다. 따라서, 방사성 동위원소가 표지된 테스토스테론을 기질로 하여 효소반응 시킨 후, 박막크로마토그래피법과 이미지 분석기를 이용하여 테스토스테론으로 부터 전환된 디하이드로테스토스테론의 양을 측정함으로써 5알파-리덕타아제의 활성을 계산하였다.5-alpha-reductase serves to convert testosterone to dihydrotestosterone. Therefore, after enzymatic reaction using testosterone labeled with radioisotopes as a substrate, the activity of 5 alpha-reductase was calculated by measuring the amount of dihydrotestosterone converted from testosterone using thin-film chromatography and image analyzer. It was.
도 1에서 보듯이 박막크로마토그래피법과 이미지 분석기를 이용하여 테스토스테론과 디하이드로테스토스테론 각각을 분리하여 정량적으로 측정가능한 것을 확인하였다.As shown in FIG. 1, testosterone and dihydrotestosterone were separated using thin film chromatography and an image analyzer, and it was confirmed that they were quantitatively measured.
실시예Example
3: 테스토스테론 3:
5알파-리덕타제 효소의 활성억제력을 알아보기 위하여 5알파 리덕타제 효소를 발현하는 세포주인 LNCaP 또는 DU145 (American Type Culture Collection, CRL-1740, HTB-81)을 48시간 동안 배양한 후 기질인 [3H] 테스토스테론과 토사자 추출물, 괴화 추출물, 맥문동 추출물 각각을 처리하여 다시 12시간 배양하였다. 반응이 끝난 후, 배양액을 에틸아세테이트로 2번 추출하고 박층 크로마토그래피법을 이용 해 분리한 후 이미지 플레이트(image plate)에 옮기고 이미지 분석기 (Fuji, BAS-1000)를 이용하여 방사선능(radioactivity)를 통해 생성된 DHT의 양을 측정하였다. 테스토스테론이 DHT로 전환(conversion)되는 비율은 0.5% DMSO 를 처리한 대조군에서 생성된 DHT양에 대한 상대값을 계산하여 비교하였다.To investigate the activity-inhibitory activity of 5-alpha-reductase enzyme, LNCaP or DU145 (American Type Culture Collection, CRL-1740, HTB-81), which expresses 5-alpha reductase enzyme, was incubated for 48 hours and then the substrate [ 3 H] Testosterone and Tosa extract, lumped extract, and Macmundong extract were treated and incubated for another 12 hours. After the reaction, the culture solution was extracted twice with ethyl acetate, separated by thin layer chromatography, transferred to an image plate, and radioactivity was analyzed using an image analyzer (Fuji, BAS-1000). The amount of DHT produced was measured. The rate at which testosterone is converted to DHT was compared by calculating the relative value for the amount of DHT produced in the control treated with 0.5% DMSO.
효소 저해제의 효능을 나타내는 지표인 IC50 값은 추출물의 농도를 달리하여 처리한 후 측정된 DHT 생성비율에 대해 아래 수식을 적용하여 계산하였다.The IC50 value, which is an indicator of the efficacy of the enzyme inhibitor, was calculated by applying the following formula to the measured DHT production rate after treatment with different extract concentrations.
각 추출물의 5알파-리덕타아제 저해 효과Inhibitory Effect of Each Extract on 5-alpha-reductase
실시예 4: C57BL/6 마우스의 모발 성장에 미치는 영향 평가Example 4 Evaluation of the Effect on Hair Growth of C57BL / 6 Mice
삭제delete
토사자 (兎絲子), 맥문동(麥門冬), 괴화(槐花)로부터 얻은 추출물의 경피 도포가 동물의 모발 성장에 미치는 영향을 평가하기 위하여 C57BL/6 마우스(입수처: (주) 코아텍)를 제모하고 다음날 피부가 선홍색(휴지기)인 동물만을 실험에 사용하였다. 추출물의 경피 도포는 매일 1회 실시하였으며, 이때 동일 부위에 10 회씩 문지르는 방법으로 도포하였다. 모발 성장에 미치는 영향은 시험기간 중 도포 면적 대비 모발이 자라나는 면적(%)을 측정하였고, 시험기간 종료 시 도포 부위 2 × 2.5 cm 의 면적 내에서 자란 모발의 무게를 측정하여 비교함으로써 평가하였다.To evaluate the effect of transdermal application of extracts from Tosa, Macmun-dong, and lump flower on hair growth in animals, C57BL / 6 mice (Source: KOATEC Co., Ltd.) ) And the next day only skin-red (pause) animals were used in the experiment. Transdermal application of the extract was performed once daily, at which time it was applied by rubbing 10 times on the same site. The effect on the hair growth was measured by measuring the area of hair growth (%) relative to the application area during the test period, and was evaluated by comparing the weight of the hair grown within the area of the
이상에서 설명한 바와 같이, 본 발명에 따른 토사자, 괴화, 맥문동 추출물들은 테스토스테론 5알파-리덕타아제 저해 효과가 우수하므로 이들을 유효성분으로 함유하는 전립선 비대증, 여드름, 탈모 예방 및 치료의 원료, 건강식품, 화장품, 생약제로 사용할 수 있다.As described above, the extracts of earth and sand, lumps, ganmundong according to the present invention has
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060053227A KR100832404B1 (en) | 2006-06-13 | 2006-06-13 | Extract of Cuscutae Semen for preventing production of hair loss causative agent and its composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060053227A KR100832404B1 (en) | 2006-06-13 | 2006-06-13 | Extract of Cuscutae Semen for preventing production of hair loss causative agent and its composition |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080011375A Division KR100852263B1 (en) | 2008-02-04 | 2008-02-04 | Extract of Liriopis Tuber for preventing production of hair loss causative agent and its composition |
KR1020080011374A Division KR100845786B1 (en) | 2008-02-04 | 2008-02-04 | Extract of Sophorae Flos for preventing production of hair loss causative agent and its composition |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070118921A KR20070118921A (en) | 2007-12-18 |
KR100832404B1 true KR100832404B1 (en) | 2008-05-26 |
Family
ID=39137440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060053227A KR100832404B1 (en) | 2006-06-13 | 2006-06-13 | Extract of Cuscutae Semen for preventing production of hair loss causative agent and its composition |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100832404B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019112348A1 (en) * | 2017-12-06 | 2019-06-13 | 주식회사 바이로메드 | Herbal composition for preventing or treating benign prostatic hyperplasia disease |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101154219B1 (en) * | 2009-12-23 | 2012-06-18 | 주식회사 리베코스 | Cosmetic composition comprising the herbal mixed extract comprising poria cocos showing hair-growth stimulating activity and preventing activity from hair loss |
KR101427035B1 (en) * | 2013-02-13 | 2014-08-05 | 김순일 | Composition for treating acne |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950006061B1 (en) * | 1991-09-18 | 1995-06-08 | 주식회사태평양 | Hair growing composition |
-
2006
- 2006-06-13 KR KR1020060053227A patent/KR100832404B1/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950006061B1 (en) * | 1991-09-18 | 1995-06-08 | 주식회사태평양 | Hair growing composition |
Non-Patent Citations (1)
Title |
---|
Korean J. Pharmacog. 35(4), pp. 375-379, 2004 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019112348A1 (en) * | 2017-12-06 | 2019-06-13 | 주식회사 바이로메드 | Herbal composition for preventing or treating benign prostatic hyperplasia disease |
KR20190067126A (en) | 2017-12-06 | 2019-06-14 | 주식회사 헬릭스미스 | Herbal Compositions for Treating and Preventing Benign Prostatic Hyperplasia |
CN111465403A (en) * | 2017-12-06 | 2020-07-28 | 赫利世弥斯株式会社 | Herbal composition for preventing or treating prostatic hypertrophy |
KR102167811B1 (en) * | 2017-12-06 | 2020-10-21 | 주식회사 헬릭스미스 | Herbal Compositions for Treating and Preventing Benign Prostatic Hyperplasia |
JP2021505628A (en) * | 2017-12-06 | 2021-02-18 | ヘリックスミス カンパニー, リミテッド | Herbal composition for the prevention or treatment of benign prostatic hyperplasia disease |
JP7035294B2 (en) | 2017-12-06 | 2022-03-15 | ヘリックスミス カンパニー, リミテッド | Herbal composition for the prevention or treatment of benign prostatic hyperplasia disease |
Also Published As
Publication number | Publication date |
---|---|
KR20070118921A (en) | 2007-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pandit et al. | Effect of Cuscuta reflexa Roxb on androgen‐induced alopecia | |
KR101315813B1 (en) | Hair cosmetic | |
JPH1067674A (en) | Abnormal accumulation suppressor of extracellular matrix | |
KR101310980B1 (en) | The cosmetics and functional food composition for improving anti-oxidant, anti-inflammatory and anti-wrinkling containing lycium chinense mill stem extracts | |
JP2007008885A (en) | Hair growing agent | |
Patel et al. | A comparative in vivo and in vitro evaluation of hair growth potential of extracts and an isolate from petroleum ether extract of Cuscuta reflexa Roxb | |
KR100832404B1 (en) | Extract of Cuscutae Semen for preventing production of hair loss causative agent and its composition | |
JPH0570360A (en) | Androgenic hormone-resistant agent | |
KR101654308B1 (en) | Composition for improving hair having effect of depilation prevention and good hair | |
JP3091962B2 (en) | Testosterone-5α-reductase inhibitor | |
KR100852263B1 (en) | Extract of Liriopis Tuber for preventing production of hair loss causative agent and its composition | |
KR20070074690A (en) | Testosterone 5alpha-reductase inhibitor containing elsholtziae herba extract | |
KR100845786B1 (en) | Extract of Sophorae Flos for preventing production of hair loss causative agent and its composition | |
KR101066797B1 (en) | Hair growth agent composition | |
JP2001187742A (en) | Testosteron-5-alfa-reductase inhibitor | |
JP2014185130A (en) | Hair cosmetic for hair growth | |
KR101724870B1 (en) | Wnt/-catenin Activity promoting composition of Wnt/-catenin signaling with Anthriscus sylvestris Hoffm extract | |
JP2011219462A (en) | Cosmetic or phamaceutical composition containing kuzu flower extract | |
KR102131299B1 (en) | Composition for preventing or treating inflammation comprising Glycine max (L.) Merrill variety SCEL-1 seed extract | |
JP2008189558A (en) | TESTOSTERONE 5alpha-REDUCTASE INHIBITOR | |
JP5896618B2 (en) | Melanin production inhibitor | |
JP2010065008A (en) | Anti-androgenic hormone preparation, and hair papilla cell proliferation enhancer, and preparation for external use for scalp and hair | |
JP3165832B2 (en) | Antiandrogens | |
JP2005145902A (en) | TESTOSTERONE-5alpha-REDUCTASE INHIBITOR | |
JP2009001523A (en) | Antiandrogenic agent, hair grower and hair cosmetic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120518 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20130308 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140915 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150520 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160513 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20171120 Year of fee payment: 10 |
|
LAPS | Lapse due to unpaid annual fee |